Have you been diagnosed hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, locally advanced or metastatic breast cancer, and have not received any systemic anti-cancer treatment for the disease. The study will explore the effects of the study drug PF-07220060 plus letrozole and if it is more effective compared to currently approved drugs (palbociclib, abemaciclib, or ribociclib) in combination with letrozole. This study is different from your regular medical care. The purpose of your regular medical care is to manage or improve your health, but the purpose of research is to gather information to advance science and medicine and does not replace your regular medical care.

Do you have a CD19 positive hematologic malignancy? Has your disease returned after responding to initial treatment (relapsed) or is not responding to treatment (refractory)? If so, you may be able to participate in this gene therapy research study.

Do you have early-stage breast cancer that is considered low-risk by your doctor? If yes, you might be able to join a research study. In this study, we are testing if taking a lower dose of the medicine tamoxifen is a better treatment for you than the usual hormone therapy.

Have you been diagnosed with Stage 4 HER2 positive (HER2+) breast cancer? If so, you may be able to take part in a research study to test the safety and effectiveness of a sequence of drugs (a taxane plus trastuzumab plus pertuzumab followed by trastuzumab Deruxtecan, followed by tucatinib plus Ado-trastuzumab emtansine (T-DM1), followed by trastuzumab plus pertuzumab plus tucatinib) to learn whether the treatment works in treating your type of cancer. The study will help us understand whether first intensifying therapy for a specific period and then stopping treatment is safe and effective for patients who receive this therapy.

Are you a woman with a history of breast cancer (Stage 0-III)? Do you identify as Black/African-American? Do you struggle with fear or worry that your cancer may return? If you are a breast cancer survivor that identifies as Black/African-American, you may be eligible to participate in the FoRtitude Interview Study. Compensation provided.

Have you been diagnosed with HER2-low locally unresectable advanced or metastatic breast cancer? If so, you may be eligible for a study to investigate the efficacy treatment with Dato-DXd or T-DXd.

Do you have metastatic or incurable, recurrent head and neck cancer? If so, you may be able to participate in a research study to find out if a new investigational drug, in combination with pembrolizumab, can help people with advanced head and neck cancer.

Have you been diagnosed with Ovarian Cancer? Have you received cytoreductive surgery? If so, you may be able to take part in a study on a new ovarian cancer treatment. We want to find out if taking a medicine called Olaparib for one year works as well as the usual treatment for ovarian cancer. We also want to see if Olaparib can help stop the cancer from growing or coming back.

Have you been diagnosed with early stage triple negative breast cancer and not yet received treatment? If so, you may be eligible for a trial comparing the use two different regimens of chemotherapy-immunotherapy treatments prior to surgery.

Do you have solid tumor of the lung or esophagus? Have the standard treatments for your condition been ineffective or not tolerable? If so, you may be eligible to participate in an early phase research study of the investigational drug YL201 as a possible treatment for advanced solid tumors.